Acinetobacter sp. VT-511

Acinetobacter sp. VT-511, Isolated from the Stomach of a Patient with Gastric Cancer

It has become clear that microorganisms contribute to the development and progression of oncogenesis. Therefore, the isolation of novel bacteria directly from the site of oncological processes is of primary interest. We recently isolated one such bacterium, Acinetobacter sp. VT-511. This organism comprises a novel species of Acinetobacter that was isolated from the stomach of a patient with gastric cancer. Genetic analyses revealed that the organism encodes gene sequences predicted to encode macrolide-specific efflux proteins and ABC, MATE, and RND family multidrug resistance transporters. In addition, the organism harbors genes that would provide resistance to ethidium bromide, fluoroquinolones, macrolides, fosmidomycin, and bacteriocin, as well as genes encoding virulence factors such as adhesins, polysaccharides, peptidases, and proteases.

CITATION

Tetz, G., & Tetz, V. (2015). Draft Genome Sequence of Acinetobacter sp. strain VT-511 Isolated from the Stomach of a Patient with Gastric Cancer. Genome Announcements3(5), e01202-15.

Read article

Draft Genome Sequence of Acinetobacter sp. strain VT-511 Isolated from the Stomach of a Patient with Gastric Cancer

Publication Type Journal Article
Authors George Tetz

Victor Tetz

Abstract We report the draft genome sequence of Acinetobacter sp. strain VT-511, which was obtained from the stomach of a patient with gastric cancer. The genome of Acinetobacter sp. VT-511 is composed of approximately 3,416,321 bp and includes 3,214 predicted protein-coding genes.
Year of Publication 2015
Journal Genome announcements
DOI 10.1128/genomeA.01202-15